Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis

详细信息    查看全文

• 作者：Franciszek G?ówka (1)
  Marta Kara?niewicz-?ada (1)
  Edmund Grze?kowiak (2)
  Dominika Rogozinska (1)
  Wojciech Romanowski (3)
  
• 关键词：Stereoselective pharmacokinetics ; Bioavailability ; Cytochrome P450 ; Pharmacogenetics ; Capillary zone electrophoresis
• 刊名：European Journal of Drug Metabolism and Pharmacokinetics
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：36
• 期：3
• 页码：167-173
• 全文大小：260KB
• 参考文献：1. Baek SJ, Wilson LC, Lee CH, Eling TE (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301:1126-131 CrossRef
  2. Bertucci C (2001) Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. Chirality 13:372-78 CrossRef
  3. Caillé G, du Souich P, Besner JG, Gervais P, Vezina M (1989) Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med 86:38-4 CrossRef
  4. Foster RT, Jamali F, Russell AS, Alballa SR (1998) Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses. J Pharm Sci 77:191-95 CrossRef
  5. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JAG (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76:119-27 CrossRef
  6. G?ówka FK (2002) Determination of ketoprofen enantiomers in human serum by capillary zone electrophoresis. Man pharmacokinetic studies after administration of rac-ketoprofen tablets. J Pharm Biomed Anal 30:1035-045 CrossRef
  7. G?ówka FK, Kara?niewicz M (2004) High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. J Pharm Biomed Anal 35:807-16 CrossRef
  8. G?ówka FK, Kara?niewicz-?ada M (2008) CE determination of ketoprofen enantiomers in clinical samples of plasma, synovial fluid and urine. Chromatographia 67:S97–S105 CrossRef
  9. Heinzel G, Woloszczak R, Thomann P (1993) Pharmacokinetic and pharmacodynamics data analysis system for the PC. Gustav Fischer, Stuttgard
  10. Ishizaki T, Sasaki T, Suganuma T, Horai Y, Chiba K, Watanabe M, Asuke W, Hoshi H (1980) Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. Eur J Clin Pharmacol 18:407-14 CrossRef
  11. Kara?niewicz-?ada M, ?uczak M, G?ówka F (2009) Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica 39:476-85 CrossRef
  12. Mehanna AS (2003) NSAIDs: chemistry and pharmacological actions. Am J Pharm Edu 67:1-
  13. Niwa Y, Iio A, Niwa G, Sakane T, Tsunematsu T, Kanoh T (1990) Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J Clin Lab Immunol 31:11-6
  14. Park JY, Sohn JH, Yoon YR, Shon JH, Cha IJ, Seo SS, Choi JS, Shin JG (2001) Disposition kinetics of ketoprofen into synovial fluid following systemic administration: population pharmacokinetic analysis. J Korean Soc Clin Pharmacol Ther 9:97-07
  15. Rodrigues AD (2005) Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metabol Disp 33:1567-575 CrossRef
  16. Rudy AC, Liu Y, Brater C, Hall SD (1998) Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. J Clin Pharmacol 38:3-0
  17. Sallustrio BC, Purdie YJ, Whitehead AG, Ahern MJ, Meffin PJ (1988) The disposition of ketoprofen in man. Br J Clin Pharmacol 26:765-70
  18. Skeith KJ, Russell AS, Jamali F (1993) Ketoprofen pharmacokinetics in the elderly: influence of rheumatic disease, renal function and dose. J Clin Pharmacol 33:1052-059
  
• 作者单位：Franciszek G?ówka (1)
  Marta Kara?niewicz-?ada (1)
  Edmund Grze?kowiak (2)
  Dominika Rogozinska (1)
  Wojciech Romanowski (3)
  
  1. Depatment of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 6 ?wi?cickiego Street, 60-781, Poznań, Poland
  2. Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, 14 ?w. Marii Magdaleny Street, 61-861, Poznań, Poland
  3. Poznan Rheumatology Center in ?rem, 95 Mickiewicza Street, 63-100, ?rem, Poland
  

文摘

Pharmacokinetics of ketoprofen (KTP) enantiomers has been studied in patients with rheumatoid arthritis (RA) following administration of a single oral dose of 100?mg rac-KTP during multidrug therapy taking into consideration the genotype of RA patients Concentrations of (?-R and (+)-S enantiomers of KTP in plasma, urine and synovial fluid samples were determined using a validated HPCE method. The genotype of the patients was analyzed using PCR-RFLP method to determine the polymorphic variants of genes coding CYP2C8 and CYP2C9 isoenzymes. The levels of KTP enantiomers in synovial fluid at 4?h following administration were insignificantly greater [(?-R?=?1.34?±?0.91?mg/L; (+)-S?=?1.38?±?0.91?mg/L] than in plasma [(?-R?=?1.15?±?0.95?mg/L; (+)-S?=?1.22?±?0.95?mg/L]. The values of AUC0?∞ were 11.89?±?5.00 and 10.92?±?4.10?mg?h/L for (?-R and (+)-S enantiomer, respectively, and were lower compared with data obtained in healthy volunteers following administration of the same dose of rac-KTP. But, no statistically significant differences were observed also for C max, Cl, V d, t 0.5 and MRT of KTP enantiomers. The total percentage of unchanged KTP eliminated with urine of RA patients was in the range of 30-0% of the administered dose. Though RA patients represented the same wild genotype, quite significant variabilities (Cl(?-R ?=?2.37-3.50?L/h and Cl(+)-S ?=?2.44-.90?L/h) existed in the pharmacokinetics parameters of KTP. We concluded that KTP data obtained from healthy volunteers cannot be sufficient to predict disposition of KTP enantiomers in RA patients, especially when undergoing long-term multidrug therapy.